LLY LLY
Eli Lilly CFO Confirms Q2 2026 Target for FDA Approval of Oral Obesity Pill Orforglipron
Eli Lilly CFO Lucas Montarce confirmed the company's timeline for its oral obesity drug, orforglipron, at the JPMorgan Healthcare Conference. Lilly targets...
Eli Lilly stock dips amid broader market decline, holding near analyst targets
Eli Lilly (LLY) traded down 0.68% at $1073.62 on January 13, 2026, following a positive analysis from Simply Wall St that emphasized strong share price...
Eli Lilly and Nvidia Announce $1B AI Lab for Drug Discovery
Eli Lilly and Nvidia announced a major collaboration to launch an artificial intelligence co-innovation lab. Unveiled at the J.P. Morgan Healthcare Conference,...
Eli Lilly Reportedly Prepares €15 Billion Bid for French Biotech Abivax
Eli Lilly is reportedly preparing a €15 billion offer to acquire French biotechnology firm Abivax. The U.S. pharmaceutical giant has not yet submitted a formal...
Eli Lilly's Taltz and Zepbound Combination Therapy Succeeds in Phase 3b Psoriatic Arthritis Trial
Eli Lilly released positive topline results from the Phase IIIb TOGETHER-PsA study. The trial combined the arthritis drug Taltz (ixekizumab) with the...
Eli Lilly Expands AI Drug Discovery Access Through New Collaborations
Eli Lilly and Company partnered with Revvity and Schrödinger to expand access to its artificial intelligence (AI) drug discovery models. The initiative, named...
Eli Lilly shares little changed in pre-market as Zacks names it 'Bull of the Day'
Eli Lilly shares are trading modestly higher pre-market at $1088.85 after Zacks Equity Research selected the company as its “Bull of the Day,” emphasizing its...
Eli Lilly shares little changed as insider sale and obesity-pill optimism balance out
Eli Lilly received a significant boost after UBS raised its price target to $1,250, maintaining a bullish outlook on the company's robust obesity pipeline,...
Eli Lilly-Backed Aktis Oncology Raises $317.7 Million in IPO
Aktis Oncology Inc., a clinical-stage biotechnology company, raised $317.7 million in its initial public offering. The Boston-based firm is backed by Eli Lilly...
Eli Lilly shares little changed in after-hours trading ahead of January 9 session
A recent Form 4 filing revealed that Lilly Endowment Inc. executed a significant insider sale on January 7, offloading 293,446 shares of Eli Lilly for...
Eli Lilly Expands AI Drug Discovery and Immunology Pipeline with New Collaboration and Potential Acquisition
Eli Lilly and Company announced a collaboration with BigHat Biosciences to advance its machine-learning biologics discovery platform, TuneLab. BigHat will...
Eli Lilly Announces Major Obesity Drug Partnership and Is in Talks for $1B+ Acquisition, Fueling Stock Surge
Eli Lilly and Company stock surged on January 7, 2026. The rise followed two major announcements bolstering its position in the high-growth obesity drug...
🟢 LLY is trading 3.7% up today on reports of $1B+ Ventyx Biosciences acquisition talks
LLY is trading at $1103.03 (+3.7%) amid reports of advanced talks to acquire Ventyx Biosciences for over $1 billion. * Ventyx's experimental pills target...
Eli Lilly Expands Obesity Pipeline with $1.3B Nimbus Therapeutics Collaboration
Eli Lilly and Company announced a multi-year collaboration with Nimbus Therapeutics. The partnership focuses on developing a novel preclinical oral obesity...
LLY rebounds 1.14% in live trading after pre-market decline amid GLP-1 competition and 2026 catalysts
Eli Lilly shares initially experienced pre-market volatility but recovered strongly, closing up 1.14% at $1,053.42, as investors focused on the company's...
Eli Lilly Slashes Mounjaro Price in China by Nearly 70%
Eli Lilly drastically cut the price of its weight-loss drug, Mounjaro, in the Chinese market. The monthly cost for the lowest dose fell nearly 70%. The price...
LLY Declines 3.6% on January 5 Amid Profit-Taking; Maintains Strong Buy Rating
Eli Lilly shares dropped 3.6% to $1,041.51 as investors engaged in profit-taking following a significant recent surge, despite the stock maintaining a highly...
Indiana Sues Eli Lilly Over Alleged Insulin Price-Fixing Scheme
Indiana Attorney General Todd Rokita filed a new lawsuit against Eli Lilly on December 31, 2025, alleging an insulin price-fixing scheme. The lawsuit claims...
🔴 LLY is trading 3% down today as rival Novo Nordisk begins selling obesity pill in U.S.
LLY is trading at $1045.85 (-3.19%) following reports of a 4% drop linked to competitor Novo Nordisk launching its obesity pill in the U.S., intensifying...
LLY down 0.78% in pre-market to $1071.90 after Leerink raises PT to $1234
Investment firm Leerink Partners significantly raised its price target on Eli Lilly (LLY) to $1234 (up from $1104), maintaining an Outperform rating based on...